J&J/Amgen Bundling Dispute Could Lead To Stricter CMS Accounting Rules
Executive Summary
Johnson & Johnson is moving on several fronts to counter Amgen pricing and discount policies it alleges are anti-competitive, and one result could be the Centers for Medicare & Medicaid Services (CMS) requiring more detailed discount reporting in the Medicare arena
You may also be interested in...
Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics
Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.
Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission
Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S
Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission
Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S